Indirect treatment comparisons of nusinersen versus onasemnogene abeparvovec-brve in treatment-naïve and -experienced spinal muscular atrophy patients
Open Access
- 12 November 2026
- journal article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2700-2717
Abstract
No abstract availableFunding Information
- Biogen
This publication has 31 references indexed in Scilit:
- Systematic Review and Meta-analysis of Long-Term Nusinersen Effectiveness in Adolescents and Adults with Spinal Muscular AtrophyAdvances in Therapy, 2025
- Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysisNeurology and Therapy, 2024
- A Critical Appraisal of Matching-Adjusted Indirect Comparisons in Spinal Muscular AtrophyAdvances in Therapy, 2023
- Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular AtrophyClinical Pharmacology & Therapeutics, 2021
- Validity and Reliability Analysis of the PlotDigitizer Software Program for Data Extraction from Single-Case GraphsPerspectives on Behavior Science, 2021
- PRO109 A Cautionary TALE for Indirect Treatment Comparisons: An Example from Infantile-Onset Spinal Muscular AtrophyValue in Health, 2020
- European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophyEuropean Journal of Paediatric Neurology, 2020
- Adeno-associated virus vector as a platform for gene therapy deliveryNature Reviews Drug Discovery, 2019
- Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose–response Study in Mice and Nonhuman PrimatesMolecular Therapy, 2015
- The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJournal of Clinical Epidemiology, 1997